Dr. Jeremy J. Day
University of Alabama at Birmingham
University of Alabama at Birmingham
Eric J. Nestler, M.D., Ph.D.
Nash Family Professor of Neuroscience Director
Friedman Brain Institute Dean for Academic and Scientific Affairs
Icahn School of Medicine at Mount Sinai
New York, NY USA
Nash Family Professor of Neuroscience Director
Friedman Brain Institute Dean for Academic and Scientific Affairs
Icahn School of Medicine at Mount Sinai
New York, NY USA
Kerri D. Pryce1, Hope Kronnman1, Aarthi Ramakrishnan1, Claire Polizu, Anne Ruiz1, Sevasti Gaspari, Catherine Jensen-Pena2, Angelica Torres-Berrios1, Vassiliki Mitsi1, Matthew Jarpe3, Ralph Mazitshek3, John van Duzer3, Li Shen1, Eric Nestler1 and Venetia Zachariou1.
1Nash Family Department of Neuroscience and Friedman Brian Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029
2Princeton Neuroscience Institute, Princeton, New Jersey
3Regenancy Pharmaceutics. Boston MA, USA
Dr. Jennifer Tuscher
University of Alabama at Birmingham
Dr. Linda Dwoskin
University of Kentucky
Shoptaw, S; Clark JL; Goodman
Dr. Sarah Withey
Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (F.B.d.M., S.L.W., J.B.) and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (F.B.d.M., S.L.W., J.B.).
THE REVIEW PROCESS
Dr. Mary Custer
Dr. Ikhlas Khan
University of Mississippi
Mahmoud A. ElSohly, Ph.D, BCFM, BCFE
University of Mississippi
Dr. Ziva Cooper
UCLA Cannabis Research Initiative, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of
CaliforniaDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of CaliforniaDepartment
of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California
Dr. David E Olson
UC Davis
Eleana Solakidou1,3, Monica H. Dawes2, Chandrashekhar Honrao1, Xiaoyu Ma1, Alexandros Makriyannis1, Elena H. Chartoff2, Rajeev I. Desai1,2
1Northeastern University, Center for Drug Discovery, Boston, MA
1Northeastern University, Center for Drug Discovery, Boston, MA
2Harvard Medical School-McLean Hospital, Belmont, MA
3University of Crete, Medical School, Heraklion, Greece
Dr. Kenzie L. Preston
NIDA
epidemiologic methods for detecting novel psychoactive substances in the u.s.
Linda B. Cottler, PhD, MPH, FACE
NDEWS Department of Epidemiology
Brenda Winn1, Chungsik Kim2, Meng Cui1, Roman Manetsch1,2, Diomedes Logothetis1
1Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston 02115
2Department of Chemistry and Chemical Biology, College of Sciences, Northeastern University, 360 Huntington Ave, Boston 02115
Mohammed Mustafa, Joel Schlosburg, Jayden Elmer, and Aron H. Lichtman
Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA